Syros Pharmaceuticals, Inc.
35 CambridgePark Drive
4th Floor
Cambridge, MA 02140
United States
617 744 1340
https://www.syros.com
版塊: Healthcare
行業: Biotechnology
全職員工: 68
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Richard A. Young Ph.D. | Scientific Founder, Member of Scientific Advisory Board & Director | 101.02k | 無 | 1954 |
| Dr. David A. Roth M.D. | Chief Medical Officer | 633.43k | 無 | 1963 |
| Mr. Conley Chee | CEO, President & Director | 無 | 無 | 1970 |
| Dr. James E. Bradner M.D. | Founder | 無 | 無 | 1972 |
| Dr. Nathanael S. Gray Ph.D. | Scientific Founder & Member of Scientific Advisory Board | 無 | 無 | 無 |
| Mr. Jason Haas | Chief Financial Officer | 426.21k | 無 | 1968 |
| Ms. Karen Hunady M.S. | Director of Corporate Communications & Investor Relations | 無 | 無 | 無 |
| Mr. Gerald E. Quirk Esq., J.D. | Chief Legal Officer & Head of Business Development | 118.45k | 無 | 1968 |
| Ms. Lisa Roberts | Vice President of Human Resources | 無 | 無 | 無 |
| Ms. Kristin Stephens | Chief Development Officer | 無 | 無 | 1973 |
描述
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
公司管治
截至 2024年4月1日 止，Syros Pharmaceuticals, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：7；董事會：7；股東權利：8；現金賠償：8。
